Xian Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xian Wu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Cong Wang
Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai 810001, P.R. China
1 shared publicationCui Li
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
1 shared publication- Dong-Yang Zhang
School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou China
1 shared publication - Gui-Qiu Zhao
Department of Ophthalmology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
1 shared publication Hui Li
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
1 shared publication- Jianqin Wei
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication
Latest Publications
- Open Access
- 4 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (2) , 2071-2077
The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells (Review)
Chemokine ligand 25 (CCL25) and chemokine receptor 9 (CCR9) are important regulators of migration, proliferation and apoptosis in leukocytes and cancer cells. Blocking of the CCR9/CCL25 signal has been demonstrated to be a potential novel cancer therapy. Research into CCR9 and CCL25 has revealed their associated upstream and downstream signaling pathways; CCR9 is regulated by several immunological factors, including NOTCH, interleukin 2, interleukin 4 and retinoic acid. NOTCH in particular, has been revealed to be a crucial upstream regulator of CCR9. Furthermore, proteins including matrix metalloproteinases, P‑glycoprotein, Ezrin/Radixin/Moesin and Livin are regulated via phosphatidylinositol‑3 kinase/ protein kinase B, which are in turn stimulated by CCR9/CCL25. This is a review of the current literature on the functions and signaling pathways of CCR9/CCL25.
- 4 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (2) , 2071-2077
Open AccessThe role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells (Review)
Chemokine ligand 25 (CCL25) and chemokine receptor 9 (CCR9) are important regulators of migration, proliferation and apoptosis in leukocytes and cancer cells. Blocking of the CCR9/CCL25 signal has been demonstrated to be a potential novel cancer therapy. Research into CCR9 and CCL25 has revealed their associated upstream and downstream signaling pathways; CCR9 is regulated by several immunological factors, including NOTCH, interleukin 2, interleukin 4 and retinoic acid. NOTCH in particular, has been revealed to be a crucial upstream regulator of CCR9. Furthermore, proteins including matrix metalloproteinases, P‑glycoprotein, Ezrin/Radixin/Moesin and Livin are regulated via phosphatidylinositol‑3 kinase/ protein kinase B, which are in turn stimulated by CCR9/CCL25. This is a review of the current literature on the functions and signaling pathways of CCR9/CCL25.